<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253912</url>
  </required_header>
  <id_info>
    <org_study_id>VBP-245-WART2A</org_study_id>
    <nct_id>NCT04253912</nct_id>
  </id_info>
  <brief_title>Topical 2% Povidone-Iodine Gel in Verruca Vulgaris</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Study to Evaluate Topical 2% Povidone-Iodine Gel (VBP-245) in Subjects With Verruca Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veloce BioPharma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veloce BioPharma LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled phase 2 study in
      subjects 8 years of age and older who present with verruca vulgaris (common warts) and desire
      treatment. Subjects may have up to a total of 6 common warts located on their trunk or
      extremities that will be treated with study medication and followed throughout the study
      protocol therapy. All warts will be treated two times per day (BID) for12 weeks.
      Approximately 90 subjects will be enrolled in this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in wart diameter (mm)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of wart</measure>
    <time_frame>12 weeks</time_frame>
    <description>Wart diameter = 0 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Application Site Reaction Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Warts</condition>
  <arm_group>
    <arm_group_label>VBP-245</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical 2% Povidone-Iodine Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Gel (no Povidone-Iodine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VBP-245</intervention_name>
    <description>2% Povidone-Iodine Gel</description>
    <arm_group_label>VBP-245</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Gel (no Povidone-Iodine)</intervention_name>
    <description>Placebo Gel (no Povidone-Iodine)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to comprehend and is willing to sign an informed consent/assent for
             participation in this study.

          -  Male or female â‰¥ 8 years old.

          -  Subject has a clinical diagnosis of verruca vulgaris (common warts).

          -  Subject has up to 6 warts located on the trunk or extremities

        Exclusion Criteria:

          -  Subject has clinically atypical warts on the trunk or extremities.

          -  Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic
             immunodeficiency, transplant status, etc.)

          -  Subject has periungual, subungual, genital, anal, mosaic, plantar, flat, or filiform
             wart identified as a wart for study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Barone, MD</last_name>
    <role>Study Director</role>
    <affiliation>Veloce BioPharma LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel Barone, MD</last_name>
    <phone>2023908590</phone>
    <email>sbarone@velocebiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Sugarloaf</city>
        <state>Pennsylvania</state>
        <zip>18429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Fort Mill</city>
        <state>South Carolina</state>
        <zip>29708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veloce BioPharma Clinical Trial Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Aggregate data will be shared with study investigators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

